Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Assets (2016 - 2025)

Historic Current Assets for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $354.7 million.

  • Theravance Biopharma's Current Assets rose 20451.32% to $354.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $354.7 million, marking a year-over-year increase of 20451.32%. This contributed to the annual value of $161.1 million for FY2024, which is 2061.24% up from last year.
  • As of Q3 2025, Theravance Biopharma's Current Assets stood at $354.7 million, which was up 20451.32% from $366.3 million recorded in Q2 2025.
  • Theravance Biopharma's Current Assets' 5-year high stood at $511.7 million during Q3 2022, with a 5-year trough of $116.5 million in Q3 2024.
  • In the last 5 years, Theravance Biopharma's Current Assets had a median value of $204.6 million in 2022 and averaged $238.9 million.
  • Its Current Assets has fluctuated over the past 5 years, first tumbled by 6840.25% in 2023, then soared by 20701.8% in 2025.
  • Theravance Biopharma's Current Assets (Quarter) stood at $249.9 million in 2021, then skyrocketed by 41.46% to $353.5 million in 2022, then plummeted by 62.22% to $133.5 million in 2023, then rose by 20.61% to $161.1 million in 2024, then surged by 120.22% to $354.7 million in 2025.
  • Its Current Assets was $354.7 million in Q3 2025, compared to $366.3 million in Q2 2025 and $150.3 million in Q1 2025.